INTRODUCTION
Immune-mediated inflammatory diseases (IMIDs) refer to a group of chronic conditions that share common inflammatory pathways [1] . IMIDs include conditions such as inflammatory bowel disease (IBD), psoriasis (PS) and rheumatologic conditions (RC) including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA). IMIDs affect approximately 5-7% of Western populations and can have a detrimental effect on quality of life and health outcomes [1] . In line with other chronic conditions, sub-optimal adherence to treatment has been reported in a number of systematic reviews. Persistence or adherence rates to treatments for IMIDs were found to range from 30% to 80% in RA [2], 7% to 72% in IBD [3] , and 33% to 78% in PS [4] .
Increasing adherence may have a far greater impact on health outcomes than advances in medical treatments [5, 6] . There are also associated economic implications such as increased medication costs, resources used including hospital admissions, inadequate use of healthcare professionals' time, and increased sickness-related work absence [7] . Thus, understanding the key drivers of non-adherence to the types of treatments used across IMIDs is an important area of investigation and key for the development of effective strategies to tackle non-adherence. Further, the identification of generic tools and/or interventions common to IMIDs would enable the identification of key areas likely to be important for adherence and assist the clinician to identify and address patient concerns in their consultations.
Although there are existing systematic reviews looking at factors associated with non-adherence in the individual clinical areas (i.e., RA, IBD, or PS), there is a clear need for a broad understanding of the determinants of adherence across IMIDs [2-4, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] .
AIMS
To our knowledge, no systematic review to date has examined factors associated with adherence across several IMIDs or included multiple treatment types. The purpose of the current review is, therefore, to examine factors associated with adherence in selected IMIDs across rheumatology, gastroenterology and dermatology in a systematic way. This could enable the identification of associations not only in each therapeutic area but also those in common across the therapeutic areas. Identification of key factors will allow interventions to focus on areas most likely to have an impact on non-adherence. If there are factors that are found to be common across these IMIDs, this will afford the opportunity to develop cross-condition tools for the health care professional (HCP) both to identify areas of non-adherence risk and for generic interventions, which may be particularly useful for rheumatologists who are likely to treat patients with different manifestations of their IMIDs.
METHODS
The systematic review followed guidelines developed by the National Institute for Clinical Excellence (NICE) and the Centre for Reviews and Dissemination, University of York [18, 19] .
Literature Search and Selection
A search of the literature was conducted via the following online databases: PubMed, Science Direct, PsychINFO and the Cochrane Central
Register of Clinical Trials. A broad search strategy was developed to capture each disease within the examined clinical areas (see Fig. 1 ).
In addition, the reference lists of relevant articles identified through the database search and existing systematic reviews were searched manually to identify further suitable studies.
The search was limited to articles published from January 1, 1980 to February 14, 2014 . The reason for limiting the search to articles published after January 1980 was that a previous systematic review identified that general research interest in treatment adherence began around 1980 [3] .
The search was conducted individually for each of the selected IMIDs within the five clinical areas: RA, AS, PsA and IBD and PS. Initially, the titles and abstracts of the articles identified through the search strategies were screened by a first reviewer for eligibility (SB, AF or DB). The full text was then obtained for all shortlisted studies and independently reviewed by a second reviewer (AB). Disagreements between the two reviewers were resolved by discussion and independently assessed by a third reviewer (EV or JW).
Inclusion/Exclusion Criteria
Studies were eligible for inclusion in the review if they met all the criteria below:
• Published/in press between January 1, 1980 and February 14, 2014.
• Written in English language.
• Included patients with a diagnosis of RA, AS or PsA, IBD, or PS.
• Based primarily on adult samples (C18 years).
• Included statistics to examine associations of factors with non-adherence.
• Used a specified measure of adherence (validated or non-validated).
• Included adherence measurement of injection or infusion, oral, rectal or transdermal formulation (excluding parenteral nutrition).
• Contained primary quantitative data.
• All participants were on a disease-specific treatment.
• Full study published in a peer-review journal (i.e., not a conference abstract).
Studies in other clinical indications were included as long as specific information on one of the conditions of interest was explicit within the results. The decision was taken to exclude studies examining adherence to topical treatments alone, as topical treatments are not used across all three clinical areas and are typically prescribed in mild cases of PS only.
Quality Appraisal
Quality assessment was carried out for each study to examine their susceptibility to bias in terms of rigor, methods and analysis. A 16-item quality checklist adapted from a previous systematic review of a similar nature [3] 
AddiƟonal search terms used in the IBD review:
AND ibd.Ɵ,ab. OR (inflammatory adj bowel adj disease).Ɵ,ab. OR UC.Ɵ,ab. OR (ulceraƟve adj coliƟs).Ɵ,ab. OR (crohn's adj disease).Ɵ,ab. OR crohn$.Ɵ,ab.
AddiƟonal search terms used in the Psoriasis review:
AND psoriasis.Ɵ,ab. OR psoriaƟc.Ɵ,ab.
Fig. 1 Search terms
Although studies were not excluded or ranked according to quality, an overall quality score, based on the total number of quality criteria met, was computed for each study. Quality scores were used as general indicators for each study and are presented in the overview tables of included studies. Common quality limitations are explored in more detail in the ''Results'' section.
Data Extraction and Synthesis
Studies identified through each individual search were combined for data synthesis and extraction. For each eligible study, data were extracted by the first reviewer using a standardized form consisting of 23 items, which included details of measures that could potentially relate to non-adherence.
Details of the sample, non-adherence measure and potential associates examined were extracted and tabulated by the first reviewer and verified by the second and third reviewers. There was an 85% initial agreement in the data extracted and all discrepancies were resolved through discussion between the reviewers. Due to the heterogeneity of the included studies, it was not possible to perform a meta-analysis of the findings. Frequencies and proportions of studies examining similar variables and any association observed were calculated to offer a simple indication of the level of evidence. As such, the evidence was primarily synthesized in a narrative review and quantified in terms of the proportions of studies finding an association. As no two studies controlled for the same variables and the quality of these studies varied considerably, preference was not given to findings from adjusted analyses. Where associations were found for a factor and these were all in the same direction, the association was considered to be consistent.
Compliance with Ethical Guidelines
This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
RESULTS

Included Studies
A total of 73 studies met the inclusion criteria and were included in the combined review: RC = 26 (RA = 23; AS = 1; PsA = 11); IBD = 36; PS = 11 . Details regarding the study selection and exclusion process followed are presented in Figs. 2, 3 and 4. A summary of the characteristics of the studies and the factors examined in each study are shown in Tables 1, 2 and 3 Studies from the same authors were checked for overlapping samples, and where there was overlap in the samples, the studies examined different possible predictors of adherence [69, 70] . The sample size of the studies varied considerably, ranging from 28 to 12,750
participants. The vast majority of studies (90.4%) were based on samples from Europe (n = 37, 51%) or North America (n = 30, 41%). Participants were derived from outpatient clinics in the majority of samples. In RC, this was 76.9% (n = 20), in IBD (n = 25, 69.4%) and in PS (n = 8, 72.7%). One sample in RC [23] was recruited in a clinical trial and two samples in IBD [69, 79] were convenience samples recruited online through social media or IBD forums. The remaining samples were established cohorts drawn from medical or pharmacy databases.
The proportion of longitudinal studies (including retrospective cohorts) was 57.8%
(n = 15) in RC, 36.1% (n = 13) in IBD, and 72.7% (n = 8) in PS. While a substantial proportion of studies had a longitudinal design, factors were most often examined as concurrent associates of adherence and not as prospective predictors. Thus, in the current review all factors are considered as potential associates of adherence.
A large proportion of studies (57.5%) used self-report measures to assess adherence. In RC, the medication event monitoring system (MEMS) was used to measure non-adherence in three studies [28, 34, 44] , others used pill counts and pharmacy refill data [22, 23, 27] or plasma analysis [21] . Five studies had a measure of medication persistence (i.e., continuation with a medication) as the adherence outcome, obtained via HCP report [36, 38] or patient records/case notes [25, 26, 45] . In IBD, three studies combined self-report measurement with a biochemical measure [39, 53, 59] . One study assessed adherence using a biological measure only [58] and another via infusion appointment attendance [12] . The remaining five studies ArƟcles subject to abstract review n= 201
Excluded based on abstract n=148
Full arƟcles retrieved for in-depth review n=53
Excluded n=27
Included studies n=26
ArƟcles idenƟfied: Electronic search: n= 1199 Hand searches: n=4 Total: n=1203
Duplicates removed and arƟcles excluded based on Ɵtle n=1002 Fig. 2 Flowchart of included studies: rheumatologic conditions, reasons for exclusion of final 27 studies included: did not statistically examine factors associated with adherence (n = 8, original search) (n = 7, update search), full study data not reported (n = 1, original search), did not define measure of adherence (n = 9, original search) (n = 1, update search), intervention examined in relation to adherence (n = 1, original search)
used a proxy measure of adherence via prescription refill data [41, [49] [50] [51] 76] . In PS, two studies assessed adherence using a proxy measure from prescription refill data [83, 85] . A further three studies had a measure of medication persistence as the adherence outcome obtained from patient medical records [86] [87] [88] . Two studies assessed adherence with respect to unused treatment medication ascertained via pill counts weight [89, 92] .
Quality of Included Studies
The proportion of quality criteria met by each study varied widely across the three clinical areas, ranging between 31% and 87.5% in RC, 25% and 93.8% in IBD, and 25% and 58.3% in PS. The included studies in RC typically met the highest proportion of quality criteria, whereas those in PS met the least. Quality criteria most commonly not met related to details of the study required to enable an assessment of bias.
Full arƟcles retrieved for in-depth review n=56
Excluded n= 20
Included studies Total: n=36
ArƟcles subject to abstract review n=175
Excluded based on abstract n=119
ArƟcles idenƟfied: Electronic search: n=1325
Duplicates removed and arƟcles excluded based on Ɵtle n=1150 Fig. 3 Flowchart of included studies: inflammatory bowel disease, reasons for exclusion of final 20 studies included: did not statistically examine factors associated with adherence (n = 10, original search) (n = 1, update search), did not define measure of adherence (n = 5, original search), intervention examined in relation to adherence (n = 2, original search), adherence examined in sample of pregnant women only (n = 2, original search)
A number of studies did not report details of eligibility criteria (n = 15, 20.5%) or the number of participants not consenting to participate in the study (n = 42, 57.5%), so it was not possible to make an assessment of biases due to participant selection. Similarly, failure to report how missing data were treated (n = 65, 89%) and control for confounders (n = 35; 52%) was common preventing an assessment of the strength of the associations found. The majority of studies did not report power calculations (n = 56, 77%) to estimate their sample sizes and as such it was difficult to assess whether studies were adequately powered to detect associations. However, several studies had very small sample sizes that were unlikely to result in adequate power for the statistics applied.
Full arƟcles retrieved for in-depth review n=30
Excluded n=19
Included studies n=11
ArƟcles subject to abstract: n=92
Excluded based on abstract n=62
ArƟcles idenƟfied: Electronic search: n=527
Duplicates removed and arƟcles excluded based on Ɵtle n=435 Fig. 4 Flowchart of included studies: psoriasis reasons for exclusion of final 19 studies included: did not statistically examine factors associated with adherence (n = 7, original search) (n = 6, update search), examined topical treatments only (n = 5, original search), intervention examined in relation to adherence (n = 1, original search) Factors found to be associated with treatment adherence highlighted in bold aTNF anti-tumor necrosis factor, MPR medication possession ratio,
NR not recorded, QoL quality of life, SD standard deviation
Overview of Findings
Adherence rates varied considerably in all clinical areas and ranged between 7% and 75% in RC, 4% and 72% in IBD, and 8% and 87% in PS. Evidence of an association of rates according to the adherence measure type (e.g., self-report, MEMs, biochemical, medication possession ratio) was not found. Factors assessed in relation to non-adherence were collated into four key categories: demographic; clinical; treatment; and psychosocial. All the factors explored across two or more chronic conditions, or in one condition and in a minimum of two studies with consistent results are presented in Table 4 . The table summarizes the frequency of studies examining these factors and proportion of studies to find a statistically significant association.
Demographic Factors
Age and gender were the most commonly examined factors (79.5% and 80.8%) in relation to adherence across conditions. The majority of studies to examine them (n = 38, 65.5% and n = 44, 74.6%, respectively) found no association with adherence and, where these were found, the findings were not consistent.
The exception was for IBD where older age was found to be associated with greater likelihood of adherence in all studies to find an association (n = 11). However, an association was found in only a minority of the IBD studies; the majority (i.e., 18 out of 29) found age not to be associated with adherence. Marital status, education level, socioeconomic status, employment status, income, insurance type, geographical location and ethnicity were not consistently associated with non-adherence across diseases.
Clinical Factors
Clinical factors were the second most commonly examined (see Table 4 ). Disease duration and disease activity were the two clinical factors examined most frequently (n = 37 and n = 28). However, only a small proportion of these studies (21.6% and 25%)
found an association with adherence, and where associations were found, the relationship was not found to be consistent. In some cases, the relationship between disease duration and activity was positively associated with adherence, while in others there was a negative association. Disease severity and lesion location, although only examined in a minority of studies (n = 10 and n = 2), reported the most consistent associations. In the PS studies, disease severity was the most commonly examined clinical factor in relation to adherence (45.5%). An association with adherence was found in three of these studies (60%), in which patients with lower disease severity were more likely to be non-adherent to their PS treatment than those with greater disease severity [84, 90, 92] . Only two of the five IBD studies (40%) to examine this reported an association between disease severity and adherence and the direction of this association conflicted. None of the included RC studies examined disease severity. Location of psoriatic lesions was examined in two of the PS studies (18%).
Non-adherence was found to be more likely among patients with facial lesions compared to those with lesions restricted to the rest of the body or with increasing number of lesion sites [92] and among those with greater body surface area of lesions [72] . Further details about these studies are available in the Tables 1, 2 , 3 and 4.
Table 4
Number of studies to examine factor and to find an association with non-adherence according to individual condition and overall Table 4 continued 
Treatment Factors
Medication type, dosing frequency, and previous treatment showed the most frequent association with adherence in the treatment category. Medication type was the most commonly explored treatment factor, which was assessed in 40 studies (54.8%) with an association to non-adherence reported in over half of these studies (52.5%).
In RC, non-steroidal anti-inflammatory drugs (NSAIDs) were found to be associated with lower adherence levels than disease-modifying medications [conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs)] in one study [28] . Another study found an association only for patients on steroids with these more likely to be adherent than those patients on NSAIDs or csDMARDs [40] , although no association with corticosteroid use was observed in the other study examining this [36] . Among anti-tumor necrosis factor (TNF) treatments, significantly higher discontinuation rates and lower adherence levels were found for the biologic infliximab compared to the biologic etanercept and adalimumab [31, 38] . In IBD, greater adherence was associated with patients receiving anti-TNF (versus Prednisolone, Budesonide, exclusive enteral nutrition and 5-aminosalicylic acid (5-ASAs)
[58], immunomodulator (versus 5-ASA) [46, 54, 56] , and steroid treatments compared to those who prescribed other medications (including 5-ASAs, immunosuppressants and antibiotics) [74] . In another study, non-adherence was reported to be more frequent in treatment with 5-ASAs compared to treatment with thiopurines and biological therapy [75] . Patients on oral treatment were more likely to be adherent compared to those on topical and enema treatments in another study [53] .
Persistence rates were significantly higher for patients taking non-sulfasalazine 5-ASA compared to those taking sulfasalazine 5-ASA in one study [76] , whereas in another study persistence was higher for those prescribed a multi-matrix system mesalamine 5-ASA compared to those prescribed balsalazide, mesalamine delayed release or sulfasalazine 5-ASAs [81] . In PS, six studies looked for associations according to biological DMARD, with higher persistence to adalimumab or etanercept compared to infliximab in one study [88] , higher persistence to etanercept compared to both adalimumab and infliximab in another study [87] and higher persistence to ustekinumab compared with other anti-TNFs found in two studies [86, 91] . The other two studies found no difference in levels of adherence between adalimumab and etanercept [85] or between alefacept, efalizumab or etanercept [83] . The number of doses taken daily was explored in seven studies across the diseases, of which the majority found an association (71.4%, n = 5). While the dosing frequencies examined varied between studies, associations were consistent, in that a greater likelihood of adherence to treatment was found with less frequent dosing.
Previous treatment was explored in five studies, four of which found an association with adherence (80%). Three of these studies reported that previous exposure to the same drug or similar type of treatment increased the likelihood of non-adherence/early discontinuation [31, 88, 92] . This may be due to confounding factors such as lack of efficacy or acquired resistance to the drug class. The remaining study, reported that not having used rectal 5-ASA or immunosuppressive/biologic agents, was associated with the risk of non-persistence and non-adherence to 5-ASAs [81] .
Psychosocial Factors
Thirteen psychosocial factors were examined in relation to adherence (see Table 4 ). Psychosocial factors were most commonly examined in the studies of IBD, followed by RC and were rarely examined in studies of PS. Treatment beliefs (i.e., necessity, concerns and efficacy), emotional well-being (depression and anxiety), HCP-patient relationship, treatment self-efficacy (i.e., confidence in one's ability to follow treatment) and practical barriers (e.g., frequent traveling, forgetfulness, etc.) were found to be associated with non-adherence in at least 50% of the studies to examine these.
Non-adherence was found to be associated with doubts about treatment necessity in 55.6% of the studies to examine this [29, 40, 57, 68, 75] .
Similarly, concerns about side effects and low perception of treatment efficacy were found to be associated with non-adherence in 70% and 50% of studies to examine this, respectively [29, 33, 39, 40, 57, 68, 78, 84] . Four of the ten studies in RC and IBD to examine depression found a consistent association with non-adherence, with greater non-adherence reported amongst patients with depression or depressive symptoms. For anxiety, while over a third of the studies to examine this (n = 3, 37.5%) found an association with non-adherence, the direction of association was inconsistent. No studies assessed depression or anxiety in patients with PS. Practical barriers (e.g., frequent traveling, forgetfulness, etc.) were explored in six studies, and five of these found non-adherence to be more likely when practical barriers to taking treatment were perceived to be present. There was also some evidence that low levels of trust and satisfaction in the HCP-patient relationship may increase treatment non-adherence, with an association reported in 77.8% of the studies to examine this [32, 37, 40, 43, 71, 74, 77] . This factor was not examined in any of the PS studies. Lower treatment self-efficacy was significantly and consistently associated with poorer medication adherence in all three studies of RC [23, 28, 39] . This factor was not examined in any of the IBD or PS studies.
DISCUSSION
This is the first review to systematically examine factors associated with non-adherence to treatment specifically for patients with selected IMIDs across three clinical areas. Demographic factors were the most commonly examined in relation to non-adherence followed by clinical and treatment factors. Psychosocial factors were examined in a minority of studies in RC and IBD and rarely examined in the PS studies.
However, several consistent associations with adherence were observed for psychosocial factors that appear independent of the therapeutic area assessed. [94, 95] , less frequent dosing was associated with increased adherence, which may reflect the lower demand on memory and planning for the patient. However, it was not possible to assess whether there was a dosing frequency above which the likelihood of treatment non-adherence is increased, again due to wide heterogeneity in dosing frequencies assessed.
Psychosocial factors were only explored in a minority of studies. Despite heterogeneity in measures used, several consistent associations were observed. In particular, the current review found evidence that lower perceptions of treatment necessity [29, 40, 57, 68, 75] and of treatment efficacy [78, 84] , greater treatment concern [39, 78, 84] and higher HCP-patient discordance [32, 37, 40, 43, 71] Evidence of an association of poorer emotional well-being, particularly depression, with non-adherence was found in the current review. Associations between anxiety and non-adherence on the other hand were less consistent, indicating that if an association exists, this may be weaker. These findings are consistent with those of a systematic review of studies of patients across a range of chronic conditions [97] . Both reviews suggest that depression but not anxiety may be a risk factor for treatment non-adherence in IMIDs, as well as chronic conditions more generally. This finding is of high importance, as depression is a potentially modifiable factor if diagnosed and treated appropriately, thus reducing the likelihood of poor adherence. It also raises an important question about the nature of the process in this effect. For example, depression might have effects on memory and planning ability, as well as on beliefs about treatment and efficacy [97, 98] .
Treatment self-efficacy may also be an important factor for treatment adherence.
Thus, patients with stronger beliefs in their ability to follow treatment were found to be more likely to adhere than those with comparatively weaker self-efficacy beliefs.
Although, this was only examined in studies of RC, previous systematic reviews have found treatment self-efficacy to be closely related to adherence in a number of different chronic conditions [96] . However, to enable firm conclusions to be drawn, further research is needed to investigate these factors among patients specifically with PS and IBD.
Evidence of an impact of practical barriers in treatment adherence was also found in the current review. The category of practical barriers is broad and can encompass many 
